Exagen Inc. (NASDAQ:XGN) Major Shareholder Nmsic Co-Investment Fund, L.P. Sells 200,000 Shares

Exagen Inc. (NASDAQ:XGN) major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $3.30, for a total value of $660,000.00. Following the completion of the sale, the insider now directly owns 2,108,958 shares of the company’s stock, valued at approximately $6,959,561.40. This trade represents a 8.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Exagen Stock Performance

Shares of XGN opened at $3.97 on Friday. The company has a market capitalization of $70.03 million, a PE ratio of -4.22 and a beta of 1.35. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The company’s 50 day moving average price is $3.00 and its 200 day moving average price is $2.55. Exagen Inc. has a 52 week low of $1.30 and a 52 week high of $4.83.

Exagen (NASDAQ:XGN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The business had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $13.55 million. During the same period in the previous year, the company posted ($0.31) EPS. Research analysts expect that Exagen Inc. will post -0.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Exagen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Verus Capital Partners LLC bought a new stake in shares of Exagen in the 3rd quarter valued at approximately $39,000. Creative Planning acquired a new stake in Exagen in the third quarter valued at approximately $110,000. Renaissance Technologies LLC grew its position in Exagen by 93.3% in the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after acquiring an additional 45,476 shares in the last quarter. Palumbo Wealth Management LLC increased its stake in shares of Exagen by 14.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after purchasing an additional 9,695 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after purchasing an additional 175,701 shares in the last quarter. 75.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, William Blair reissued an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).